Principal Financial Group Inc. Reduces Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Principal Financial Group Inc. decreased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRXFree Report) by 7.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 50,414 shares of the company’s stock after selling 4,018 shares during the period. Principal Financial Group Inc.’s holdings in Amneal Pharmaceuticals were worth $306,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in AMRX. Jump Financial LLC purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter worth about $316,000. Charles Schwab Investment Management Inc. increased its stake in Amneal Pharmaceuticals by 3.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,302,633 shares of the company’s stock worth $5,497,000 after acquiring an additional 47,599 shares during the last quarter. EMC Capital Management increased its stake in Amneal Pharmaceuticals by 886.7% in the 3rd quarter. EMC Capital Management now owns 40,613 shares of the company’s stock worth $171,000 after acquiring an additional 36,497 shares during the last quarter. Tejara Capital Ltd bought a new position in Amneal Pharmaceuticals in the 3rd quarter worth about $408,000. Finally, WINTON GROUP Ltd increased its stake in Amneal Pharmaceuticals by 172.3% in the 3rd quarter. WINTON GROUP Ltd now owns 51,922 shares of the company’s stock worth $219,000 after acquiring an additional 32,854 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on AMRX shares. The Goldman Sachs Group upped their target price on Amneal Pharmaceuticals from $6.25 to $8.00 and gave the stock a “buy” rating in a research note on Monday, May 6th. Truist Financial restated a “buy” rating and issued a $9.00 target price (up from $7.00) on shares of Amneal Pharmaceuticals in a research note on Monday, May 6th. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Piper Sandler increased their price objective on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Buy” and an average target price of $8.25.

View Our Latest Stock Report on Amneal Pharmaceuticals

Amneal Pharmaceuticals Trading Up 1.1 %

Shares of AMRX stock opened at $6.68 on Wednesday. The stock has a market capitalization of $2.06 billion, a PE ratio of -11.93 and a beta of 1.19. Amneal Pharmaceuticals, Inc. has a 1-year low of $2.29 and a 1-year high of $6.98. The business has a 50-day moving average of $6.21 and a 200 day moving average of $5.70. The company has a debt-to-equity ratio of 121.31, a current ratio of 1.65 and a quick ratio of 0.97.

Amneal Pharmaceuticals (NASDAQ:AMRXGet Free Report) last issued its earnings results on Friday, May 3rd. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.04. The company had revenue of $659.19 million during the quarter, compared to analysts’ expectations of $623.08 million. Amneal Pharmaceuticals had a positive return on equity of 234.06% and a negative net margin of 6.76%. As a group, sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.51 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

(Free Report)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Read More

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NASDAQ:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.